Tony Summerlin - CBrain AS Chief America
| CBRAIN Stock | DKK 179.00 8.40 4.48% |
Insider
Tony Summerlin is Chief America of cBrain AS
| Phone | 45 72 16 18 11 |
| Web | https://www.cbrain.com |
CBrain AS Management Efficiency
The company has return on total asset (ROA) of 0.1265 % which means that it generated a profit of $0.1265 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2764 %, meaning that it generated $0.2764 on every $100 dollars invested by stockholders. CBrain AS's management efficiency ratios could be used to measure how well CBrain AS manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Mns Barsne | Ambu AS | N/A | |
| Danilo Verge | Zealand Pharma AS | N/A | |
| Rolf Hoffmann | Genmab AS | 60 | |
| Jens MD | Zealand Pharma AS | N/A | |
| Christina Bredal | Zealand Pharma AS | 38 | |
| Henriette Wennicke | Zealand Pharma AS | N/A | |
| Michael Packert | ChemoMetec AS | N/A | |
| Thomas Johansen | Netcompany Group AS | 53 | |
| Tine Boye | Netcompany Group AS | N/A | |
| Steen Sondergaard | ChemoMetec AS | 64 | |
| Ravinder Chahil | Zealand Pharma AS | N/A | |
| Thomas Henriksen | Ambu AS | 50 | |
| Claus Jorgensen | Netcompany Group AS | 56 | |
| Mikkel Wagner | Ambu AS | N/A | |
| Paolo Paoletti | Genmab AS | 68 | |
| Britt Jensen | Ambu AS | 50 | |
| Jonathan Peacock | Genmab AS | 61 | |
| Adam MD | Zealand Pharma AS | 49 | |
| Ivan Moller | Zealand Pharma AS | 51 | |
| Thomas Schmidt | Ambu AS | 52 | |
| Birgitte MSc | Genmab AS | 62 | |
Management Performance
| Return On Equity | 0.28 | |||
| Return On Asset | 0.13 |
cBrain AS Leadership Team
Elected by the shareholders, the CBrain AS's board of directors comprises two types of representatives: CBrain AS inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CBrain. The board's role is to monitor CBrain AS's management team and ensure that shareholders' interests are well served. CBrain AS's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CBrain AS's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Niels Kristensen, Director Affairs | ||
| Thomas Qvist, CTO, Director and Member of Audit Committee | ||
| Robert Lentz, Chief Officer | ||
| Per Knudsen, Founder, CEO, Director and Member of Audit Committee | ||
| Ejvindgensen, CFO Relations | ||
| Tony Summerlin, Chief America |
CBrain Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CBrain AS a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.28 | |||
| Return On Asset | 0.13 | |||
| Profit Margin | 0.21 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 3.34 B | |||
| Shares Outstanding | 19.56 M | |||
| Shares Owned By Insiders | 46.24 % | |||
| Shares Owned By Institutions | 12.98 % | |||
| Price To Earning | 256.25 X | |||
| Price To Book | 22.11 X |
Pair Trading with CBrain AS
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CBrain AS position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CBrain AS will appreciate offsetting losses from the drop in the long position's value.Moving against CBrain Stock
The ability to find closely correlated positions to CBrain AS could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CBrain AS when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CBrain AS - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling cBrain AS to buy it.
The correlation of CBrain AS is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CBrain AS moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if cBrain AS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CBrain AS can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in CBrain Stock
CBrain AS financial ratios help investors to determine whether CBrain Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CBrain with respect to the benefits of owning CBrain AS security.